Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

123
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
123
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

225
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
225
Drug Therapy01:28

Drug Therapy

42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
42
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

172
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
172
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

114
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
114

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccine fatigue and influenza vaccination trends across Pre-, Peri-, and Post-COVID-19 periods in the United States using epic's cosmos database.

PloS one·2025
Same author

Smell and Taste Disorders in Primary Care.

American family physician·2023
Same author

Mental Health Concerns for College Students: Self-Harm, Suicidal Ideation, and Substance Use Disorders.

Primary care·2023
Same author

Smoking Cessation Interventions.

American family physician·2022
Same author

Unintentional Weight Loss in Older Adults.

American family physician·2021
Same author

Endometrial Biopsy: Tips and Pitfalls.

American family physician·2020

Related Experiment Video

Updated: Jun 25, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K

Depression: Managing Resistance and Partial Response to Treatment.

Heidi L Gaddey1, Brandyn Mason1, Amol Naik1

  • 1Carle Foundation Hospital Family Medicine Residency, Urbana, Illinois.

American Family Physician
|May 28, 2024
PubMed
Summary

Treatment-resistant depression (TRD) affects many patients despite multiple medication trials. Management involves psychotherapy, medication adjustments, or novel treatments like ketamine, electroconvulsive therapy, and transcranial magnetic stimulation.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K

Related Experiment Videos

Last Updated: Jun 25, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Treatment-resistant depression (TRD) is a significant clinical challenge, affecting up to 31% of individuals with major depressive disorder.
  • TRD is characterized by a lack of remission despite adequate trials of at least two antidepressant medications.
  • Partial response, defined as less than 50% symptom reduction, necessitates careful adherence confirmation before diagnosing TRD.

Purpose of the Study:

  • To outline current management strategies for treatment-resistant depression (TRD).
  • To review pharmacologic and non-pharmacologic interventions for TRD.
  • To discuss the role of newer treatments and the limitations of pharmacogenetic testing.

Main Methods:

  • Review of current clinical guidelines and evidence for TRD management.
  • Identification of augmentation strategies including pharmacologic and non-pharmacologic options.
  • Evaluation of emerging treatments such as ketamine, esketamine, electroconvulsive therapy (ECT), and repetitive transcranial magnetic stimulation (rTMS).

Main Results:

  • Augmentation with second-generation antidepressants, atypical antipsychotics, tricyclic antidepressants, lithium, or triiodothyronine are recommended pharmacologic options.
  • Ketamine and esketamine show potential for TRD and reducing suicidal ideation.
  • Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) are effective non-pharmacologic interventions.
  • Pharmacogenetic testing currently lacks sufficient evidence for routine clinical recommendation.

Conclusions:

  • Effective management of TRD involves a multimodal approach, including psychotherapy, medication class switching, and augmentation.
  • Novel pharmacologic agents (ketamine, esketamine) and neuromodulation techniques (ECT, rTMS) offer promising alternatives for refractory depression.
  • Confirmation of medication adherence and dose is critical prior to implementing advanced TRD strategies.